June 2nd 2025
A recap of the FDA submissions and regulatory decisions in urology from May 2025.
ASTRO on proton therapy: More research needed
March 18th 2013The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.
IPP placement post-T-shunt surgery appears efficacious
March 6th 2013Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.
Endocrine disruptors linked to PCa, cryptorchidism
February 25th 2013Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.
'Field effect' markers may detect occult prostate Ca
February 25th 2013Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
FDA grants priority review to metastatic PCa agent
February 19th 2013The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.
PDE-5 inhibitor may improve ejaculatory function
February 11th 2013New data suggest the phosphodiesterase type-5 inhibitor tadalafil (Cialis) may be beneficial in helping men who have problems with ejaculation and orgasm, report researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center, New York.
Study questions botulinum’s efficacy in post-BPH overactive bladder
December 31st 2012Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.
Minimally invasive RPLND safe, efficacious in testis cancer
December 31st 2012Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.